Patents by Inventor Frank M. Longo

Frank M. Longo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20220162177
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 26, 2022
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING COGNITIVE DYSFUNCTION
    Publication number: 20220031641
    Abstract: Provided are compositions and methods comprising agonists. Also disclosed are agonist compounds, pharmaceutical compositions of agonists, and methods of using the same.
    Type: Application
    Filed: July 21, 2021
    Publication date: February 3, 2022
    Inventors: Michelle Leigh Monje-Deisseroth, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 11225467
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 18, 2022
    Assignee: PHARMATROPHIX, INC.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 10532988
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: January 14, 2020
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20190263763
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 29, 2019
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES
    Publication number: 20190231787
    Abstract: Methods and compounds for treating alcohol use disorder and associated diseases. Included is the administering to a subject in need there of an effective amount of a compound having a modulating effect on p75NTR.
    Type: Application
    Filed: August 25, 2017
    Publication date: August 1, 2019
    Inventors: Stephen MASSA, Frank M. LONGO, Dorit RON
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 10273219
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 30, 2019
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20180037560
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Application
    Filed: August 25, 2017
    Publication date: February 8, 2018
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20180037559
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Application
    Filed: August 21, 2017
    Publication date: February 8, 2018
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 9884833
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms. In one embodiment, the crystalline compound is (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: February 6, 2018
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Non-peptide BDNF neurotrophin mimetics
    Patent number: 9828332
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 28, 2017
    Assignee: PharmatorophiX, Inc.
    Inventor: Frank M. Longo
  • Non-peptide BDNF neurotrophin mimetics
    Patent number: 9828330
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 28, 2017
    Assignee: PharmatrophiX, Inc.
    Inventor: Frank M. Longo
  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20170158653
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms. In one embodiment, the crystalline compound is (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide.
    Type: Application
    Filed: September 13, 2016
    Publication date: June 8, 2017
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • METHODS OF FACILITATING CELL SURVIVAL USING NEUROTROPHIN MIMETICS
    Publication number: 20170157127
    Abstract: Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75NTR receptor molecule. Enhanced survival of neural and other cells has been observed.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 8, 2017
    Inventors: Frank M. Longo, Stephen M. Massa
  • Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
    Patent number: 9604907
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: March 28, 2017
    Assignees: The University of North Carolina at Chapel Hill, The Regents of The University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Frank M. Longo, Stephen M. Massa
  • CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS
    Publication number: 20160176832
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Crystalline forms of neurotrophin mimetic compounds and their salts
    Patent number: 9271986
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 1, 2016
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS
    Publication number: 20160046559
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Applicant: Pharmatrophix, Inc.
    Inventor: Frank M. Longo
  • NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS
    Publication number: 20160023990
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Inventor: Frank M. Longo
  • PHARMACEUTICAL FORMULATIONS COMPRISING NEUROTROPHIN MIMETICS
    Publication number: 20150111903
    Abstract: Methods and compounds for treating neurodegenerative and other disorders. Included is the administering to a subject in need thereof an effective amount of a compound having binding specificity for a p75NTR receptor molecule. Enhanced survival of neural and other cells has been observed.
    Type: Application
    Filed: October 31, 2014
    Publication date: April 23, 2015
    Inventors: Frank M. Longo, Stephen M. Massa